Mauritius Telecom and Aprecomm Come Together to Bring Innovation to Customer Experience With Network Intelligence
28.2.2023 14:58:00 EET | Business Wire | Press release
Mauritius Telecom, the largest ISP in Mauritius with cellular and high-speed broadband service distribution, today announced its intent to bring Artificial Intelligence based innovative technology to enhance visibility and optimize its residential Wi-Fi connections through a partnership with Aprecomm. This A.I. technology will help Mauritius Telecom to bring proactive Network Intelligence transformation to improve customer experience and to drastically reduce the time for resolution of customer-end issues across their broadband network covering more than 300,000 households.
Speaking on the development, Mr. Kapil Reesaul, CEO, Mauritius Telecom, said, “Mauritius Telecom is the forefront runner in continuous investments in technology to keep innovating and providing the best service to its consumers. The partnership with Aprecomm will help us in our efforts to ensure the best experience across our broadband consumers with faster and proactive resolution of potential issues.”
Pramod Gummaraj, CEO, Aprecomm, said, “We're excited to team up with Mauritius Telecom and implement cutting-edge technology into their network in order to help them cut down on support ticket response times by as much as half and provide a dramatically better experience for their customers. Network Innovation focused on customer experience could be deployed across in the coming months.”
The measurable improvements offered by the integration between Mauritius Telecom and Aprecomm also lead to lower maintenance cost and improved customer satisfaction for one of the country’s fastest growing ISPs.
“With Aprecomm’s vendor agnostic technology, Mauritius Telecom will be able to manage and monitor Network Elements through a unified interface, ensuring assured internet experience to their customers,” said Guharajan Sivakumar, CTO, Aprecomm.
“Network Automation will allow us to bring the best possible experience to our end customers. Measurable customer experience and proactive actions to improve it will be part of this partnership as Aprecomm technology is aligned towards Network Automation,” said Mr. Yagianath Rosunee, CTO of Mauritius Telecom.
About Mauritius Telecom
Mauritius Telecom is the leading provider of an extensive range of ICT services and solutions for both residential customers and businesses in Mauritius, including fixed, mobile, broadband, TV, mobile money and ICT services. Mauritius Telecom has played a pivotal role in the socio-economic development of Mauritius, paving the way for the growth of the ICT industry, which has become a major pillar of the Mauritian economy. Mauritius Telecom has taken bold initiatives to transform the lives of Mauritians, deploying fibre island-wide to provide ultra-high-speed broadband to all, disrupting the payment landscape with a mobile wallet thus revolutionizing payments in Mauritius, launching in 2021 the first 5G Experience Zones and the first 1Gbps fibre internet to home offer in Mauritius. In 2022 Mauritius Telecom’s mobile service, my.t mobile reached the milestone of one million customers.
- Headquarters: Port Louis, Mauritius
- Website: https://www.telecom.mu, https://www.myt.mu/
- LinkedIn: https://www.linkedin.com/company/mauritius-telecom/
- Facebook: https://www.facebook.com/mauritiustelecom
About Aprecomm
Aprecomm is an industry game-changer with a Network Intelligence Software Stack to understand Customer Experience. Aprecomm offers cloud-based automated solutions to enhance Wired and Wi-Fi network performance. Aprecomm’s patented technology helps in automatically and proactively troubleshooting Wi-Fi issues. This way ISPs and Enterprises will be able to fix them immediately and dramatically minimize down-time. Aprecomm’s solutions help enterprises, ISPs, TSPs improve their business standards through higher reliability, reduced expenses, and speedy ROI.
- Headquarters: Bangalore, India
- Website: https://aprecomm.ai
- LinkedIn: https://in.linkedin.com/company/aprecomm
- Facebook: https://www.facebook.com/aprecomm/
- Twitter: https://twitter.com/aprecomm_ai
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005801/en/
Contact information
For further details please contact:
Aprecomm
Shankar Peerthy
Email: Peerthy@aprecomm.ai
Contact: +41-78 685 82 58
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
